Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children With Moderate to Severe Plaque Psoriasis

NCT06640517 is registered in ClinicalTrials.gov with Biocad as lead sponsor.

NCT NCT06640517
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06640517 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children With Moderate to Severe Plaque Psoriasis
Lead sponsor
Biocad
Phase
Phase 3
Overall status
Active, not recruiting
Start date
August 8, 2024
Completion date
February 29, 2028
Enrollment
140 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis